Rx Head-To-Head Studies Require Careful Prioritization, NIH Says
Executive Summary
NIH's role in head-to-head studies of pharmaceuticals must recognize the "limits" on the value of large comparative trials, National Institutes of Health Director Elias Zerhouni told Sen. Hillary Clinton (D-N.Y.) during an Oct. 2 hearing
You may also be interested in...
Cost-Effectiveness Makes Medicare Bill; Research Agenda Due In 6 Months
The Agency for Healthcare Research & Quality will develop a cost-effectiveness research agenda before the Medicare prescription drug benefit starts in 2006 under the Medicare Rx benefit conference agreement
Cost-Effectiveness Makes Medicare Bill; Research Agenda Due In 6 Months
The Agency for Healthcare Research & Quality will develop a cost-effectiveness research agenda before the Medicare prescription drug benefit starts in 2006 under the Medicare Rx benefit conference agreement
AHRQ Stepping Up Cost-Effectiveness Research; Says Key Is Openness
The Agency for Healthcare Research & Quality is ready to take on a new role in cost-effectiveness research, Director Carolyn Clancy, MD, said at an AHRQ National Advisory Council meeting Nov. 7